RxDoctor Payments Data

Christopher Wolfram, MD

Cardiovascular Disease · Green Bay, WINPI 1740242155

Payments from drug & device makers

$4,273in general payments, 2019–2025

Across 49 payments — averaging $87.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$1K
  • Mediview XR, Inc.$1K
  • Abbott$307
  • Boston Scientific$246
  • Inari Medical, Inc.$142
  • Johnson & Johnson$132
  • plus $583 from 15 others

What the payments were for

  • Speaking & faculty fees$1,40033%
  • Travel & lodging$1,05425%
  • Food & beverage$1,79342%
  • Education$271%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,273 in reported general payments places this provider in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$98,163
Medicare patients
358
Services billed
832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$244,419
XareltoRivaroxaban51$57,383
Repatha SureclickEvolocumab53$54,469
JardianceEmpagliflozin49$41,552
Praluent PenAlirocumab21$17,241
BrilintaTicagrelor16$13,792
NexlizetBempedoic Acid/Ezetimibe13$5,272
Rosuvastatin Calcium249$3,848
Metoprolol Succinate284$3,634
ClopidogrelClopidogrel Bisulfate295$2,980
Ezetimibe126$2,903
Atorvastatin Calcium203$2,319
Losartan Potassium140$1,613
Carvedilol136$1,366
Bumetanide37$1,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$244,419210 claims
Johnson & JohnsonXarelto$132$57,38351 claims
Boehringer IngelheimJardiance$123$41,55249 claims
AstraZenecaBrilinta$36$13,79216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →